thanks us joining to for you, and Thank today. everyone Erik,
start our excited to are mentioned to and we business we're early As we by build the encouraged earlier, year, XXXX momentum Erik the these throughout positive continue beyond. on and across as signals
basis, comparable a first the generated In $X.X quarter, billion sales in year-over-year. sales. X% increased roughly IFF On currency-neutral
revenue Biosciences Scent, strong businesses, Our and was Nourish. led Health quarterly sequential across by volume mid-single-digit including growth performance & with of our most improvements
inclusive line of have pricing to largely modestly rates markets, in positive, the changes. particular where was quarter, the that have peso, been euro Pricing drive our indexed benefit, FX-related U.S. in emerging pricing exchange pricing the with plan. negative Argentine like and/or Absent in would pricing in this industry, we, of
represents quarter with a million. and led contribution growth adjusted productivity operating delivered $XXX from the strong the EBITDA by basis, profitability We This year-over-year a XX% volume comparable initiatives. in increase on of
quarter. points XX% As approximately a adjusted result, the margins margin to in basis nearly improved operating XXX by
saw business across by volume strong to segments. basis sales Nourish, growth into very Slide X% X. comparable deeper now double-digit I'll we currency-neutral with on Turning performance our improvements price. In And strong markets. business the Flavors across and both all in dive our Flavors with a increased nearly in growth in
low up declined due since comparable planned digits, was volume single quarter of our actions. pricing first time XXXX. year-over-year the fourth Ingredients Functional currency-neutral the Overall, sales to
drove XX% EBITDA gains with and increase in of volume gross and Ingredients. profitability, In solid improvements operating comparable in a Functional both growth terms productivity margin Flavors adjusted
with another both & Health line and top growth. Biosciences segment Our bottom had quarter strong
portfolio, by Improved led in Food performance a Personal drove comparable mid-single-digit adjusted Processing in sales Home operating sales. Nutrition X% Enzymes, in Animal increase a double-digit to & currency-neutral in H&B growth Care, volume increase Grain growth comparable and gains Cultures productivity and & Solid XX% in and EBITDA. year-over-year led our
in Ingredients basis. primarily Scent outstanding Fragrance sales, delivered The which terms of Fragrance in delivered Fragrances. in Fine growth Consumer EBITDA double-digit including in productivity volume growth XX% an growth excel adjusted led growth quarter, comparable by profitability, growth of mid-single-digit and another also comparable currency-neutral by improvements, a and segment operating excellent on driven and XX%
into expected Lastly, a distributors the is in excipients from volumes noting to due distribution these destocking It's Pharma first destocking more reduce model. that of some other trends, business continued core productivity last of improvements to were market-related Solutions, due was and the in Pharma by year. while initiatives, which initiative Solutions' to late offset its as on began quarter driven worth part and we convert trend reliance direct lower saw the
with and more relationships, portfolio also are margins. be enhance as efforts Pharma direct will We thrive resources in our partnership complexity of Solutions succeed access chain Also, believe while the positioned approach to shift optimization mentioned, divest customer technical business the reduce Roquette. will as provide agreed confident improving to and to greater to we part supply our a the and business
cash quarter, of Now the while roughly on results. flow million operations impacted XX, from and normal position. CapEx $XX quarter our I'd $XXX leverage discuss Slide was million X.X% flow like our free this cash flow seasonality In to totaled Cash first or sales.
reminder, March. QX bonus usually in quarter is of we year payments the a make As flow cash annual lowest the cash as
in $XX the totaled Our flow free negative position cash period. negative quarter year-ago million versus $XX in the million
the paid also of We first million the $XXX through end quarter. dividends in
equivalents sale. $XX and including cash $XXX in Our held cash assets totaled million, for million
our debt deleveraging adjusted versus continues year at credit our billion of to for efforts almost in ago X.Xx make ratio a quarter progress debt end. gross net $X reduced by EBITDA and to IFF
credit Our $X.X approximately EBITDA adjusted trailing XX-month billion. totaled
quarterly proceeds $XXX the reflected note were of Please not and in million received that of in the the April sale results. LMC consequently from
achieve Pharma we close, the will announced net EBITDA in our are we target will transaction to Solutions the following XXXX. we confident be Xx adjusted debt credit the of half transaction, completed which of expect first With that
now ranges. On Slide XX, Based the year, our performance improved will our turn first the This mentioned, that and our improving high to for majority the now outlook balance previously operational our of remain with Erik guidance our quarter XXXX. year the reflects across to optimistic be and, expectations belief announced cautiously I'd our volumes end we X% previously financial expect like the as also towards about and ahead announced to our end towards of trend in of on trends to the portfolio. for the X% results of higher
approximately decline markets to guidance versus approximately previously pricing We quarter, X% also therefore, and expectation pricing announced that the pricing previous due FX-related would our year the in first emerging for pricing X.X%. XXXX to increases in saw full raised
now of foreign we these have FX X% an which X% versus is expected previously to our growth, exchange offsetting X% With adverse the rate pricing as changes, contribution. impact currency expect essentially sales on X% will to
XXXX, for announced line, productivity. This billion. bottom $X.X end we as are assumes billion the adjusted range strong improvements volumes towards now previously $X.X On guidance operating well EBITDA continued our in as the trending to of of high
is ability in our and it our While the still volume guidance. have year are consequently, year, encouraging, trends confidence full in to we achieve early increased
For the driven $XXX EBITDA billion with expect million operating billion, $XXX volumes approximately by to sales to we second to $X.XX of an quarter, approximately $X.XX million. adjusted be improved
turn for closing it now to back remarks. Erik I'll